Qiagen, a leading global provider of molecular diagnostics and life science research solutions, recently announced that it has entered into a definitive agreement to be acquired by Thermo Fisher Scientific, a world leader in serving science. The Qiagen Business Combination Agreement is a significant development in the life sciences industry that is expected to have a major impact on the market.
The agreement outlines the terms of the acquisition, which values Qiagen at approximately $11.5 billion. Under the terms of the agreement, Thermo Fisher will acquire all outstanding shares of Qiagen`s common stock for $43.00 per share in cash. The acquisition is expected to close in the first half of 2021, subject to regulatory approval and other customary closing conditions.
The acquisition will enable Thermo Fisher to further expand its presence in the life sciences industry, while also enhancing its capabilities in molecular diagnostics. Qiagen has a strong portfolio of molecular diagnostics products, including tests for infectious diseases, oncology, and genomics. The acquisition will also enable Thermo Fisher to access Qiagen`s extensive customer base, which includes academic research institutions, pharmaceutical companies, and diagnostic laboratories.
The acquisition will also benefit Qiagen`s customers, as they will have access to Thermo Fisher`s broad range of products and services. Thermo Fisher has a strong portfolio of life sciences products, including laboratory equipment, reagents, and consumables. This will enable Qiagen`s customers to expand their research capabilities and accelerate their scientific discoveries.
The Qiagen Business Combination Agreement represents a major development in the life sciences industry, and is expected to have a significant impact on the market. The acquisition will enable Thermo Fisher to strengthen its position in the molecular diagnostics market, while also expanding its presence in the life sciences industry. The acquisition is also expected to benefit Qiagen`s customers, who will have access to Thermo Fisher`s broad range of products and services. Overall, the Qiagen Business Combination Agreement is a positive development for the life sciences industry, and is expected to drive further innovation and growth in the years ahead.
